EP1047686A1 - Substituierte bicyclische lactone - Google Patents
Substituierte bicyclische lactoneInfo
- Publication number
- EP1047686A1 EP1047686A1 EP99904744A EP99904744A EP1047686A1 EP 1047686 A1 EP1047686 A1 EP 1047686A1 EP 99904744 A EP99904744 A EP 99904744A EP 99904744 A EP99904744 A EP 99904744A EP 1047686 A1 EP1047686 A1 EP 1047686A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- substituted
- phenyl
- different
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Definitions
- the present invention relates to substituted bicyclic lactones, processes for their preparation and their use as medicaments.
- Glutamate receptors can be divided into two broad classes: 1. ionotropic receptors that control ion channels directly and 2. metabotropic receptors (mGluRs).
- Metabotropic glutamate receptors are a heterogeneous class of G protein-coupled receptors. They pre- or post-synaptically modulate the release of glutamate or the sensitivity of the cell to glutamate. The effects are caused by different second messenger cascades. This response in turn affects the ionotropic glutamate receptors. 8 different types of metabotropic glutamate receptors are currently known, which differ in terms of second messenger cascade, pharmacology and localization in the brain (for an overview: Ann. Rev. Pharmacol. Toxicol. 1997, 37, 205).
- the present invention relates to substituted bicyclic lactones of the general formula (I)
- A represents radicals of the formulas -CH 2 -, -CO-, -CR 4 (OH) - or - (CH 2 ) a -CHR 5 -,
- a represents a number 0, 1, 2, 3 or 4,
- R 4 represents hydrogen or (C, -C 6 ) alkyl
- R 5 denotes phenyl
- R 1 represents hydrogen, (C 3 -C 6 ) cycloalkyl or a 5- to 6-membered heterocycle which contains up to 3 heteroatoms from the series S, O, N and / or a radical of the formula -NR 6 can,
- R 6 represents hydrogen or methyl
- R 7 has the meaning of R 6 given above and is the same or different with it
- b and c are the same or different and represent a number 1 or 2
- R 8 (C, -C 6 denotes alkyl or phenyl
- R 9 denotes hydrogen or (C, -C 6 ) alkyl
- R 10 and R u are identical or different and denote hydrogen, phenyl or (C, -C 6 ) - alkyl, which is optionally substituted by phenyl, which in turn is substituted one or more times, identically or differently, by halogen, nitro, hydroxy or ( C, -C 6 ) alkoxy may be substituted,
- R 10 and R 11 together with the nitrogen atom represent a radical of the formula
- R 12 is hydrogen, phenyl, benzyl, (C, -C 6 ) alkyl, (C, -C 6 ) alkoxycarbonyl or a 5- to 6-membered aromatic heterocycle with up to 3 heteroatoms from the series S, N and / or O means
- R 13 represents hydrogen, or
- (C 6 -C 10 ) aryl or 5- to 7-membered aromatic heterocycle can be substituted with up to 3 heteroatoms from the series S, N and / or O,
- a number 1 or 2 means or
- R 14 and R 15 are identical or different and are hydrogen, (C 3 -C 6 ) cycloalkyl, phenyl or (C, -C 6 ) alkyl, which is optionally substituted by (C 3 - C 6 ) cycloalkyl or phenyl which in turn can be substituted one or more times, identically or differently, by halogen, hydroxy or (C 1 -C 6 ) alkoxy,
- R 16 denotes hydrogen or (C, -C 6 ) alkyl
- R 17 denotes hydrogen, adamantyl, (C 3 -C 8 ) cycloalkyl, (C 2 -C 6 ) alkenyl or (C, -C 12 ) alkyl, which may be replaced by adamantyl, (C 3 -C 6 ) - Cycloalkyl, (C 6 -C 10 ) aryl, phenoxy or a 5- to 6-membered aromatic heterocycle with up to 3 heteroatoms from the series S, N and / or O is substituted, with aryl and the heterocycle in turn one to can be substituted several times, identically or differently by (C, -C 6 ) alkyl, (C, -C 6 ) alkoxy, hydroxy, nitro or halogen,
- R 22 (C, -C 6) alkyl or (C 6 -C I0) -aryl, which is optionally monosubstituted to polysubstituted by identical or different halogen, nitro, hydroxy or (C, -C 6) -alkoxy is
- L and M are identical or different and denote hydrogen or halogen
- R 23 and R 24 have the meaning of R 10 and R "given above and are identical or different with this,
- R ' 8 has the meaning of R 16 given above and is the same or different with this, R 19 denotes (C 3 -C 8 ) cycloalkyl, or
- R 25 , R 2 ⁇ and R 27 are the same or different and are (C, -C 6 ) alkyl
- R 20 and R 2 ' are the same or different and are hydrogen, adamantyl, (C 3 -
- R 28 and R 29 are the same or different and are hydrogen or (C, -C 6 ) alkyl, or
- R 30 has the meaning of R 12 given above and is the same or different with this,
- R 20 and R together with the nitrogen atom represent a radical of the formula
- G ' has the meaning of G given above and is the same or different with it
- R 2 and R 3 are identical or different and represent hydrogen or (C, -C 6 ) alkyl
- R 31 and R 32 are identical or different and are hydrogen or (C r C 6 ) alkyl
- R 33 is hydrogen, hydroxy, (C, -C 6 ) alkoxy, (C, -C 6 ) alkoxycarbonyl, carboxyl or (C, -C 6 ) alkyl, which is optionally by
- R 37 denotes (C, -C 6 ) alkenyl or (C, -C 6 ) alkyl, which is optionally substituted by (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl, which in turn is substituted by halogen, nitro, trifluoromethyl or (C, -C 6 ) alkyl, or is a radical of the formula -SO 2 R 38 ,
- R 38 is (C 6 -C 10 ) -alkyl or (C, -C 6 ) -alkyl
- R 34 and R 35 are identical or different and are halogen, hydroxyl, carboxyl, (C, -C 6 ) -acyloxy or amino, or
- R 34 and R 35 together with the adjacent ring carbon atom represent a radical of the formula
- R 39 denotes hydrogen or (C, -C 4 ) alkyl
- R 36 represents (C, -C 6 ) alkoxycarbonyl, or
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates to both the enantiomers or diastereomers or their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- Salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
- Salts which can be mentioned are salts with customary bases, such as, for example, alkali metal salts (for example sodium or potassium salts), alkaline earth metal salts (for example calcium or magnesium salts) or ammonium salts derived from ammonia or organic aines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine , Di benzylamine, N-methylmo holin, dihydroabietylamine, 1-ephenamine or methylpiperidine.
- alkali metal salts for example sodium or potassium salts
- alkaline earth metal salts for example calcium or magnesium salts
- ammonium salts derived from ammonia or organic aines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine , Di benzylamine, N-methylmo holin, dihydroabietylamine,
- (C 3 -C 8 ) cycloalkyl and (C 3 -) cycloalkyl stand for cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cycloheptyl or cyclooctyl.
- the following may preferably be mentioned: cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl.
- aryl generally represents an aromatic radical having 6 to 10 carbon atoms.
- Preferred aryl radicals are phenyl and naphthyl.
- (C r C alkyl. (C, -C 8 ) alkyl, (C, -C 8 ) alkyl and (C, -) alkyl stand for a straight-chain or branched alkyl radical with 1 to 12, 1 to 9, 1 to 8 or 1 to 6 carbon atoms.
- a straight-chain or branched alkyl radical having 1 to 6 carbon atoms is preferred. Examples include: methyl, ethyl, n-propyl, isopropyl, t-butyl, n-pentyl and n- Hexyl.
- (C9-C ⁇ ) -alkanediyl represents a straight-chain or branched alkanediyl radical having 2 to 8 carbon atoms.
- Propane-1,2-diyl propane-2,2-diyl, butane-1,3-diyl, butane-2,4-diyl, pentane-2,4-diyl, 2-methylpentane-2,4- diyl.
- (C 6 -C ⁇ ) -alkenediyl represents a straight-chain or branched alkenediyl radical having 2 to 6 carbon atoms, preferably having 2 to 4 carbon atoms, particularly preferably having 3 carbon atoms.
- Examples include ethene-1,2-diyl, ethene-1,1-diyl, propene-1,1-diyl, propene-1,2-diyl, propene-1,3-diyl and propene-3,3-diyl , Propene-2,3-diyl, but-2-ene-1,4-diyl, pent-2-ene-1,4-diyl, hex-2-ene-1,4-diyl.
- (C 7 -C (i ) -alkindiyl in the context of the invention represents a straight-chain or branched alkindiyl radical having 2 to 6 carbon atoms, preferably having 2 to 4 carbon atoms, particularly preferably having 2 to 3 carbon atoms.
- Examples include ethyne-1,2 -diyl, propin-1,3-diyl, but-2-in-l, 4-diyl, pent-2-in-l, 4-diyl, hex-2-in-1,4-diyl.
- (C, -) alkoxy stands for a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms.
- a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms is preferred. Examples include: methoxy, ethoxy, n-propoxy, isopropoxy, t-butoxy, n-pentoxy and n-hexoxy.
- (C, -) - alkoxycarbonyl 1 represents a straight-chain or branched alkoxycarbonyl radical having 1 to 6 carbon atoms.
- a straight-chain or branched alkoxycarbonyl radical having 1 to 4 carbon atoms is preferred. Examples include: methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl,
- (C 7 -C 8 ) alkenyl and (C 2 -C 6 ) alkenyl stand for a straight-chain or branched alkenyl radical having 2 to 8 carbon atoms or 2 to 6 carbon atoms.
- a straight-chain or branched alkenyl radical having 2 to 4 carbon atoms is preferred. Examples include: vinyl, allyl, isopropenyl and n-but-2-en-l-yl.
- (C 2 -C 6 ) -alkynyl stands for a straight-chain or branched alkynyl radical having 2 to 6 carbon atoms.
- a straight-chain or branched alkynyl radical having 2 to 4 carbon atoms is preferred. Examples include: ethynyl, n-prop-2-in-1-yl and n-but-2-in-1-yl.
- a 5- to 6-membered heterocycle generally represents a 5- to 6-membered, optionally also aromatic, heterocycle of up to 3
- Heteroatoms from the series S, O and / or N or a radical of the formula -NH or -NCH 3 can contain. Examples include: pyridyl, pyrimidyl, pyridazinyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, piperidinyl or morpholinyl. Pyridyl, pyrimidyl, pyridazinyl, furyl and thiazolyl are preferred.
- a 5- to 6-membered, benzo-condensed heterocycle generally represents a 5- to 6-membered, preferably 5-membered, heterocycle having up to 2 heteroatoms from the series S, O, N and / or a radical of Formula -NH, whose ring carbon atoms represent the points of attachment for the benzene ring.
- examples include: indolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, quinolyl, quinoxalinyl or quinazolyl.
- Benzimidazolyl quinolyl, quinoxalinyl, quinazolyl, benzothiophenyl and benzofuranyl.
- A represents radicals of the formulas -CH 2 -, -CO-, -CR 4 (OH) - or - (CH 2 ) a -CHR 5 -,
- a represents a number 0, 1, 2 or 3
- R 4 is hydrogen or (C, -C 4 ) alkyl
- R 5 denotes phenyl
- R 1 stands for hydrogen, cyclopropyl, cyclopentyl or cyclohexyl, or for benzo
- R 1 stands for hydrogen, cyclopropyl, cyclopentyl or cyclohexyl, or for benzo
- b and c are the same or different and represent a number 1 or 2
- R 8 denotes (C, -C 4 ) alkyl or phenyl
- R 9 denotes hydrogen or (C, -C 4 ) -alkyl
- R 10 and R 11 are the same or different and are hydrogen, phenyl or (C, -C 4 ) alkyl, which is optionally substituted by phenyl, which in turn is one or more times, the same or different, by fluorine, chlorine, bromine, nitro , Hydroxy or (C, -C 4 ) alkoxy may be substituted,
- R 10 and R 11 together with the nitrogen atom represent a radical of the formula
- G is an oxygen atom, a -CH 2 group or a residue of
- R ' 2 denotes hydrogen, phenyl, benzyl, (C, -C 4 ) -alkyl, (C, -C 4 ) -alkoxycarbonyl, pyridyl, pyrimidyl, pyridazinyl or furyl,
- R 13 represents hydrogen, or
- Phenyl, naphthyl, pyridyl, thienyl or furyl can be substituted
- d represents a number 1 or 2
- R 14 and R 15 are the same or different and are hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, phenyl or (C, -C 5 ) - alkyl, which is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or phenyl, which in turn is one or more times , may be substituted, identically or differently, by fluorine, chlorine, bromine, hydroxy or (C r C 4 ) -alkoxy,
- R 16 denotes hydrogen or (C, -C 3 ) alkyl
- R 17 is hydrogen, adamantyl, cyclopropyl, cyclopentyl or cyclohexyl, or (C 2 -C 4 ) alkenyl or (C, -C 10 ) alkyl, which may be replaced by adamantyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, phenoxy naphthyl , Pyridyl, thienyl or furyl is substituted, the ring systems in turn one to more, the same or different, by (C, -C 4 ) alkyl, (C, -C 4 ) alkoxy, hydroxy, nitro, fluorine, chlorine or Bromine may be substituted
- R 22 denotes (C, -C 4 ) -alkyl, phenyl or naphthyl, which are optionally substituted one or more times, identically or differently, by fluorine, chlorine, bromine, nitro, hydroxyl or (C, -C 4 ) - alkoxy,
- Phenyl, naphthyl, thienyl, furyl or pyridyl which in turn optionally one or more times, identically or differently by (C, -C 4 ) alkoxy, (C, -C 4 ) alkyl, hydroxy, nitro, fluorine, chlorine or bromine can be substituted,
- L and M are identical or different and denote hydrogen, fluorine, chlorine or bromine,
- R 23 and R 24 have the abovementioned meaning of R 10 and R u and are the same or different with this, R 18 has the meaning of R 16 given above and is the same or different with it,
- R 19 means cyclopropyl, cyclopentyl or cyclohexyl, or (C, -C 7 ) - alkyl or (C 2 -C 6 ) -alkenyl, which in turn is optionally substituted by substituents selected from the group fluorine, chlorine, bromine, phenyl, hydroxy , Morpholinyl, cyclopropyl, cyclopentyl, cyclohexyl and are substituted by a group of the formula -SiR 25 R 26 R 27 ,
- R 25 , R 2 ⁇ and R 27 are the same or different and are (C, -C 4 ) - alkyl
- R 20 and R 21 are identical or different and denote hydrogen, adamantyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, phenoxy-substituted phenyl, pyridyl, furyl, thienyl, thiazolyl or pyrryl, or
- R 28 and R 29 are the same or different and are hydrogen or (C, -C 4 ) alkyl, or
- R 30 has the meaning of R 12 given above and is the same or different with this,
- R and R together with the nitrogen atom represent a radical of the formula
- G ' has the meaning of G given above and is the same or different with it
- R 2 and R 3 are identical or different and represent hydrogen or (C, -C 3 ) -alkyl
- R and R are identical or different and are hydrogen or (C, -C 4 ) -alkyl
- R 33 is hydrogen, hydroxy, (C r C 4 ) alkoxy, (C, -C 4 ) alkoxycarbonyl, carboxyl or (C, -C 4 ) alkyl, which may be replaced by hydroxy, carboxyl or (C, -C 4 ) - Alkoxy carbonyl is substituted, or is a radical of the formula -OR 37 , wherein
- R 37 denotes (C, -C 4 ) alkenyl or (C, -C 4 ) alkyl, which is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or phenyl, which in turn is substituted by trifluoromethyl, fluorine,
- Chlorine, bromine or (C, -C 4 ) alkyl may be substituted, or denotes a radical of the formula --SO 2 R 38 ,
- R jS denotes phenyl or methyl
- R 34 and R 35 are identical or different and are fluorine, chlorine, hydroxyl, carboxyl, (C, -C 4 ) -acyloxy or amino, or (C, -C 4 ) - alkyl, which may be replaced by hydroxy or
- R represents hydrogen or methyl
- R 36 (C, -C 4 ) alkoxycarbonyl or
- A represents radicals of the formulas -CH 2 -, -CO-, -CR 4 (OH) - or - (CH 2 ) a -CHR 5 -,
- a represents a number 0, 1, 2 or 3
- R 4 is hydrogen or (C, -C 3 ) alkyl
- R 5 denotes phenyl
- R 1 represents hydrogen, cyclopropyl or cyclohexyl, or represents benzo
- R 1 represents hydrogen, cyclopropyl or cyclohexyl, or represents benzo
- benzothiophenyl benzimidazolyl
- thienyl quinazolyl or quinoxalinyl
- quinoxalinyl or
- b and c are the same or different and represent a number 1 or 2
- R 9 represents hydrogen or (C, -C 3 ) -alkyl
- R 10 and R 11 are the same or different and are hydrogen, phenyl or
- R 10 and R 11 together with the nitrogen atom represent a radical of the formula
- G represents an oxygen atom or a radical of the formula -NR 12 ,
- R 12 is hydrogen, phenyl, benzyl, (C, -C 3 ) -alkyl, (C, -C 3 ) -alkoxycarbonyl, pyridyl, pyrimidyl, pyridazinyl or furyl,
- R 13 is hydrogen, or (C, -C 6 ) - alkyl or allyl, which in turn is represented by residues of
- Phenyl, naphthyl or pyridyl can be substituted
- a number 1 or 2 means
- R 14 and R 15 are the same or different and are hydrogen, cyclohexyl, phenyl or (C, -C 4 ) alkyl, which is optionally substituted by cyclopropyl, cyclohexyl or phenyl, which in turn is one or more times, the same or different, by chlorine or (C, -C 3 ) - alkoxy may be substituted,
- R 16 denotes hydrogen, methyl or ethyl
- R 17 represents hydrogen, adamantyl, cyclopentyl or cyclohexyl, or (C 2 -C 3 ) alkenyl or (C, -C 8 ) alkyl, which may be replaced by adamantyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, phenoxy, thienyl or Furyl is substituted, whereby the ring systems can in turn be substituted one or more times, identically or differently by (C r C 3 ) alkyl, (C, -C 3 ) alkoxy, hydroxy, nitro, fluorine, chlorine or bromine ,
- R 22 denotes (C, -C 3 ) alkyl, phenyl or naphthyl, which are optionally substituted one or more times, identically or differently, by fluorine, chlorine, bromine, nitro, hydroxy or (C, -C 3 ) alkoxy,
- L and M are the same or different and denote hydrogen, fluorine or chlorine
- R 23 and R 24 have the abovementioned meaning of R 10 and R 11 and are the same or different with this,
- R 18 has the meaning of R 16 given above and is the same or different with it
- R 19 denotes (C r C 4 ) -alkyl or (C 3 -C 5 ) -alkenyl, which in turn is optionally substituted by substituents selected from the group chlorine, phenyl, hydroxy, morpholinyl, cyclopropyl, cyclohexyl and by a group of the formula - SiR 25 R 26 R 27 are substituted,
- R 25 , R 26 and R 27 are the same and are methyl
- R 20 and R 21 are identical or different and denote hydrogen, adamantyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, phenoxy-substituted phenyl, thiazolyl or pyrryl, or (C 2 -C 3 ) alkenyl, (C, -C 7 ) - Alkyl or (C 3 -C 5 ) alkynyl, which may be replaced by hydroxy, cyclopropyl, cyclopentyl, cyclohexyl, (C, -C 3 ) - alkoxy, hydroxy, trifluoromethyl, phenyl, pyridyl, furyl, thienyl or pyrryl, where the ring systems are optionally up to 2 times, identical or different, by (C, -C 3 ) alkoxy, (C, -C 6 ) alkoxycarbonyl, fluorine, chlorine, bromine, phen
- R 28 and R 29 are the same or different and are hydrogen or (C, -C 3 ) alkyl, or
- R 20 or R 21 is a radical of the formula
- R 30 has the meaning of R 12 given above and is the same or different with this,
- R 20 and R 21 together with the nitrogen atom represent a radical of the formula
- G ' has the meaning of G given above and is the same or different with it
- R 2 and R 3 are the same or different and represent hydrogen or methyl
- R 31 and R 32 are identical or different and are hydrogen or (C, -C 3 ) -alkyl
- R 33 is hydrogen, hydroxy, (C, -C 3 ) alkoxy, (C, -C 3 ) alkoxy carbonyl, carboxyl or (C, -C 3 ) alkyl, which may be replaced by hydroxy or (C, -C 3 ) -alkoxycarboxyl is substituted or denotes a radical of the formula -OR 37 ,
- R 37 denotes (C, -C 3 ) alkenyl or (C, -C 3 ) alkyl, which is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or phenyl, which in turn is substituted by trifluoromethyl, fluorine, chlorine, bromine or (C, -C 3 ) - can be substituted, or represents a radical of the formula -SO 2 R 38 ,
- R 38 means methyl
- R 34 and R 35 are identical or different and are fluorine, chlorine, hydroxyl, carboxyl, (C, -C 3 ) -acyloxy or amino, or are (C, -C 3 ) -alkyl, which may be replaced by hydroxy or
- R represents hydrogen or methyl
- R 36 means (C r C 3 ) -alkoxycarbonyl or (C, -C 3 ) -alkyl, which may be up to 2-fold, identical or different by hydroxy, (C, -C 4 ) -alkoxy or (C r C 3 ) alkoxycarbonyl is substituted,
- T represents halogen, preferably bromine
- a and R 1 have the meaning given above,
- R 40 and R 41 are the same or different and represent C ] -C 4 alkyl
- R 40 , R 41 , A and R 1 have the meaning given above,
- R 1 has the meaning given above
- Suitable solvents are all inert solvents that do not change under the reaction conditions. These preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether.
- Tetrahydrofuran is particularly preferred.
- bases are suitable as bases. These preferably include alkali metal hydroxides such as sodium or potassium hydroxide, or alkali metal carbonates such as sodium or potassium carbonate, or sodium or potassium methoxide, or sodium or potassium ethanolate or potassium tert-butoxide, or amides such as sodium amide, lithium bis (trimethylsilyl) amide , Lithiumdiisopropylamid, or organometallic compounds such as butyllithium or phenyllithium. Lithium diisopropylamide and lithium bis (trimethylsilyl) amide are preferred.
- the base is used in an amount of 1 to 5, preferably 1 to 2, mol, based on 1 mol of the compounds of the general formulas (II) and (V).
- the reactions generally take place in a temperature range from -78 ° C. to reflux temperature, preferably from -78 ° C. to + 20 ° C.
- the reactions can be carried out under normal, elevated or reduced pressure (e.g. from 0.5 to 5 bar). Generally one works at normal pressure.
- Derivatizations within the scope of the invention are preferably dihydroxylations, reductions and ether synthesis on the radicals D and E.
- the corresponding dihydroxy compounds are prepared with osmium tetroxide / N-methylmorpholine-N-oxide in inert solvents and the corresponding reduced compounds with hydrogen in the presence of a catalyst in inert solvents. It is also possible, starting from hydroxy-substituted bicycles, to introduce the ether functions through the corresponding alkyl halides in the presence of bases.
- Inert organic solvents which do not change under the reaction conditions are suitable as solvents.
- solvents include halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1, 2-dichloromethane, trichloroethane, tetrachloroethane, 1, 2-dichloroethane or trichlorethylene, hydrocarbon such as benzene, xylene, toluo, hexane, cyclohexane, or petroleum fractions, nitrile, nitrile or hexamethylphosphoric triamide. It is also possible to use mixtures of the solvents. Dichloromethane is particularly preferred.
- the usual basic compounds are suitable as bases for the derivatizations.
- bases preferably include alkali or alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal hydride such as sodium hydride, alkali metal or alkaline earth metal carbonates such as sodium carbonate, potassium carbonate, or alkali metal alcoholates such as sodium methoxide or ethanolate, potassium methoxide or ethanolate or potassium tert , or organic Amines such as benzyltrimethylammonium hydroxide, tetrabutylammonium hydroxide, pyridine, triethylamine or N-methylpiperidine.
- alkali or alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide or barium hydroxide
- alkali metal hydride such as sodium hydride
- alkali metal or alkaline earth metal carbonates such as sodium carbonate, potassium carbonate
- the derivatizations are generally carried out in a temperature range from -20 ° C to 150 ° C, preferably at 0 ° C to 25 ° C.
- the derivatizations are generally carried out under normal pressure. However, it is also possible to carry out the processes under reduced pressure or overpressure (e.g. in a range from 0.5 to 5 bar).
- the bases are generally used in an amount of 1 to 3 mol, preferably 1 to 1.5 mol, based on 1 mol of the particular carboxylic acid.
- the compounds of the general formula (I) according to the invention are suitable for use as medicaments in the treatment of humans and animals.
- the compounds of the general formula (I) according to the invention are suitable for modulating metabotropic glutamate receptors and therefore influence the glutamatergic neurotransmitter system.
- a modulator of the metabotropic glutamate receptor in the sense of the invention is a
- Agonist or antagonist of this receptor is Agonist or antagonist of this receptor.
- the compounds according to the invention are particularly suitable as modulators of the metabotropic glutamate receptor of subtype 1, very particularly as antagonists of this receptor subtype. Due to their pharmacological properties, the compounds according to the invention, alone or in combination with other medicaments for the treatment and / or prevention of neuronal damage or diseases, which have been associated with derailment of the physiological or in the case of pathophysiological conditions of the glutamaterial system in the central and peripheral nervous system are used.
- neuronal damage for example caused by ischemic, thrombic and / or thrombemolic, and hemorrhagic stroke, conditions after direct and indirect injuries in the area of the brain and skull.
- cerebral ischemia after all surgical interventions on the brain or peripheral organs or parts of the body and associated or previous conditions of a pathological or allergic nature which can primarily and / or secondarily lead to neuronal damage.
- the compounds according to the invention are also suitable for the therapy of primary and / or secondary pathological conditions in the brain, for example during or after cerebral vasospasm, hypoxia and / or anoxia of genesis not mentioned above, perinatal asphyxia, autoimmune diseases, metabolic disorders and
- Organ diseases that can be associated with damage to the brain and damage to the brain as a result of primary brain diseases, for example convulsions and arterosclerotic and / or arteriosclerotic changes.
- primary brain diseases for example convulsions and arterosclerotic and / or arteriosclerotic changes.
- neurodegenerative diseases such as Alzheimer's, Parkinson's or
- Huntington's disease multiple sclerosis, amyotrophic lateral sclerosis, neurodegeneration due to acute and / or chronic viral or bacterial infections and multi-infarct dementia.
- Dementias of different origins brain disorders in old age, memory Nest disorders, spinal cord injuries, pain, anxiety of various origins, drug-related Parkinson's syndrome, psychoses (such as schizophrenia), cerebral edema, neuronal damage after hypoglycemia, vomiting, nausea, obesity, addiction and withdrawal symptoms, CNS-mediated convulsions, sedation and Movement disorders.
- the compounds of the general formula (I) according to the invention can be used to promote neuronal regeneration in the post-acute phase of cerebral injuries or chronic diseases of the nervous system.
- They are preferably used as medicinal products for the treatment of cerebral ischemia, skull / brain trauma, pain or CNS-mediated cramps (such as epilepsy).
- the modulation of substances on the metabotropic glutamate receptor can be checked on primary cerebellar cell cultures from the cerebellum. Electrophysiological measurements on these cell cultures in the “cell attached” mode show that L-type Ca 2+ channels in this preparation are activated by mGluRI-glutamate receptors (J. Neurosci. 1995, 15, 135), whereas they are by
- Group II receptors can be blocked (J. Neurosci. 1994, 14, 7067-7076).
- the modulatory effect of pharmacological test substances on glutamate receptors can be controlled by appropriate experimental arrangement.
- a detailed check of the subtype specificity under controlled conditions can be carried out on Xenopus oocytes by injection of the corresponding mGluR subtype DNA (WO 92/10583).
- Body temperature of the animal kept at 37 ° C. After the wound has closed and the anesthetic has subsided, the animals are released back into their cages.
- the substance is administered according to different time schedules and via different application routes (i.V., i.p.) after the occlusion.
- the infarct size is determined after 7 days.
- the brain is removed, histologically processed and the infarct volume determined using a computer-assisted evaluation system.
- the animals are injected with subdural autologous blood under anesthesia. Under the
- Hematoma forms an infarction.
- the substance is administered according to different time schedules and via different application routes (i.v., i.p.).
- the infarct size is determined as described in the model of permanent focal ischemia in the rat (MCA-O).
- the anti-epileptic effect can be tested according to the method described in NeuroReport 1996, 7, 1469-1474.
- the suitability of the compounds according to the invention for testing can be determined according to the methods described in Science 1998, 281, 1349-1352 and Eur. J. Pharmacol. 1996, 316, 129-136 methods can be determined.
- the present invention also includes pharmaceutical preparations which, in addition to inert, non-toxic, pharmaceutically suitable auxiliaries and excipients, contain one or more compounds of the general formula (I), or which consist of one or several active ingredients of the formula (I), and processes for the preparation of these preparations.
- the active compounds of the formula (I) should be present in these preparations in a concentration of 0.1 to 99.5% by weight, preferably 0.5 to 95% by weight, of the total mixture.
- the pharmaceutical preparations can also contain other pharmaceutical active ingredients.
- the pharmaceutical preparations listed above can be prepared in a customary manner by known methods, for example using the excipient or excipients.
- Cis-cyclohexene-1,2-dicarboxylic anhydride (30.4 g, 200 mmol) is heated to boiling in methanol (9 ml, 220 mmol) for 1 h. The excess solvent is then evaporated. 33.2 g (180 mmol) of the monomethyl ester thus obtained are dissolved under argon in 200 ml of dry dichloromethane at 0 ° C. and oxalyl chloride (32 g, 252 mmol) is added dropwise. After the evolution of gas has ended, the mixture is stirred at room temperature for a further 3 h. The solvent is then removed in vacuo and the residue is dissolved in 75 ml of THF.
- Cis-bicyclo [2.2.1] hept-5-en-2,3-dicarboxylic anhydride (32.8 g, 200 mmol) is heated to boiling in methanol (9 ml, 220 mmol) for 1 h. The excess solvent is then evaporated. 13.5 g (74.3 mmol) of the monomethyl ester thus obtained are dissolved in 90 ml of dry dichloromethane at 0 ° C. under argon and oxalyl chloride (8.8 ml, 104 mmol) is added dropwise. After the evolution of gas has ended, the mixture is stirred at room temperature for a further 3 h. The solvent is then removed in vacuo and the residue is dissolved in 35 ml of THF. This solution is then added dropwise to a -40 ° C., argon-held solution of sodium borohydride (5.5 g, 136 mmol) in 340 ml of absolute ethanol.
- sodium borohydride 5.5 g, 136
- Tricyclo [3.2.2.0 2 ' 4 ] non-8-en-6,7-dicarboxylic anhydride (35.2 g, 200 mmol) is heated to boiling in methanol (9 ml, 220 mmol) for 1 h. The excess solvent is then evaporated. 37.4 g (180 mmol) of the monomethyl ester thus obtained are dissolved under argon in 200 ml of dry dichloromethane at 0 ° C. and oxalyl chloride (21 ml, 250 mmol) is added dropwise. After the evolution of gas has ended, the mixture is stirred at room temperature for a further 3 h. The solvent is then removed in vacuo and the residue is dissolved in 95 ml of THF.
- Example 10A fraction 1 The enantiomers (Example 10A fraction 1, and Example 10B fraction 2) were isolated by means of preparative HPLC (Chiralpak AS, isopropanol / petroleum ether 40-70 ° C. 20:80).
- Example 9A The compound from Example 9A (14.61g, 52.49 mmol) was reacted analogously to Examples 1 and 2 with N-methylmorpholine-N-oxide (12.29g, 104.97 mmol) and osmium tetroxide (2.5%) in t-butanol, 17.8 ml).
- the crude product was taken up in acetone (500 ml) and water (250 ml), at 0 ° C. with sodium periodate (16.83 g,
- Hydantoin (219 mg. 0.625 mmol), bis-tert-butyloxylcarbonyl (BOC 2 O,
- Example 21 (Fraction 4)
- Example 22 and Example 23
- the crude monoester was dissolved with 0.14 g (1.38 mmol) of triethylamine in 10 ml of THF and then 0.14 g (1.3 mmol) of ethyl chloroformate was added at -15 ° C. After stirring for one hour at room temperature, the mixture was filtered, the filtrate was concentrated and taken up in 10 ml of methanol. 0.12 g (2 mmol) of sodium borohydride was added and the mixture was stirred at room temperature overnight. For working up, ammonium chloride solution was added, the mixture was extracted three times with ethyl acetate, the combined extracts were dried over sodium sulfate and then concentrated. The The mixture was separated chromatographically on silica gel (eluent: petroleum ether / ethyl acetate). Two main fractions were obtained:
- 2nd fraction 1 - (naphth-2-ylmethyl) -2- (hydroxymethyl) cyclobutanecarboxylic acid n-butyl ester.
- the second fraction was heated in a mixture of 2.5 ml of 6N hydrochloric acid and 2.5 ml of dioxane at 60 ° C. for 2 hours. The mixture was then concentrated and in
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19801636A DE19801636A1 (de) | 1998-01-17 | 1998-01-17 | Substituierte bicyclische Lactone |
DE19801636 | 1998-01-17 | ||
PCT/EP1999/000031 WO1999036418A1 (de) | 1998-01-17 | 1999-01-07 | Substituierte bicyclische lactone |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1047686A1 true EP1047686A1 (de) | 2000-11-02 |
Family
ID=7854906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99904744A Withdrawn EP1047686A1 (de) | 1998-01-17 | 1999-01-07 | Substituierte bicyclische lactone |
Country Status (6)
Country | Link |
---|---|
US (1) | US6376539B1 (de) |
EP (1) | EP1047686A1 (de) |
JP (1) | JP2002509146A (de) |
AU (1) | AU2515799A (de) |
DE (1) | DE19801636A1 (de) |
WO (1) | WO1999036418A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19932621A1 (de) * | 1999-07-13 | 2001-04-26 | Bayer Ag | Neue substituerte alpha, beta-anellierte Butyrolactone |
US6645987B2 (en) * | 2000-06-15 | 2003-11-11 | Schering Corporation | Nor-seco himbacine derivatives useful as thrombin receptor antagonists |
JP4647861B2 (ja) * | 2001-09-20 | 2011-03-09 | コスモ石油株式会社 | (S)−(+)−5−アミノ−4−ヒドロキシペンタン酸及び(S)−(+)−γ−アミノメチル−γ−ブチロラクトンの製造方法 |
MXPA04003610A (es) * | 2001-10-18 | 2004-07-27 | Schering Corp | Analogos de himbacina como antagonistas del receptor de trombina. |
JP2011510083A (ja) * | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 3,5−二置換−1,3−オキサゾリジン−2−オン誘導体 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49110659A (de) | 1973-03-06 | 1974-10-22 | ||
NZ240921A (en) | 1990-12-12 | 1994-06-27 | Zymogenetics Inc | G protein coupled glutamate receptor (neurotransmitters), recombinant production |
GB9324872D0 (en) | 1993-12-03 | 1994-01-19 | Univ Pasteur | Pharmaceutical compounds |
US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
GB9325368D0 (en) | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
GB9325360D0 (en) | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
WO1995025110A1 (en) | 1994-03-14 | 1995-09-21 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
AU3414295A (en) | 1994-08-19 | 1996-03-14 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
EP0771196B1 (de) * | 1994-09-08 | 1999-12-08 | Eli Lilly And Company | Exzitatorische aminosäure-rezeptor-antagonisten |
JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
AU1106195A (en) | 1994-11-09 | 1996-06-06 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
US5701168A (en) | 1995-06-29 | 1997-12-23 | Bell Communications Research, Inc. | Inverse twisted and super-twisted nematic liquid crystal device |
WO1997005109A1 (en) | 1995-07-31 | 1997-02-13 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
JPH11509846A (ja) | 1995-07-31 | 1999-08-31 | ノボ ノルディスク アクティーゼルスカブ | ヘテロ環式化合物、それらの調製及び使用 |
US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
GB9605429D0 (en) | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
KR19990067598A (ko) | 1995-11-16 | 1999-08-25 | 피터 지. 스트링거 | 여기성 아미노산 유도체 |
-
1998
- 1998-01-17 DE DE19801636A patent/DE19801636A1/de not_active Withdrawn
-
1999
- 1999-01-07 JP JP2000540134A patent/JP2002509146A/ja active Pending
- 1999-01-07 WO PCT/EP1999/000031 patent/WO1999036418A1/de not_active Application Discontinuation
- 1999-01-07 EP EP99904744A patent/EP1047686A1/de not_active Withdrawn
- 1999-01-07 US US09/600,395 patent/US6376539B1/en not_active Expired - Fee Related
- 1999-01-07 AU AU25157/99A patent/AU2515799A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9936418A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002509146A (ja) | 2002-03-26 |
WO1999036418A1 (de) | 1999-07-22 |
US6376539B1 (en) | 2002-04-23 |
AU2515799A (en) | 1999-08-02 |
DE19801636A1 (de) | 1999-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69208496T2 (de) | Bernsteinsäurederivate | |
DE69433744T2 (de) | 3-amino-5-carboxy-substituierte piperidine und 3-amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten | |
DE69818538T2 (de) | Cyclopropyl-Derivate mit pharmazeutischen Eigenschaften | |
EP0089637B1 (de) | Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung | |
EP0567966B1 (de) | Cyclische Iminoderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE60309057T2 (de) | Azabicycloderivate als antagonisten des muscarinischen rezeptors | |
DE2827627C2 (de) | ||
EP0109020A2 (de) | Neue Derivate tricyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung, sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung | |
DE4132632A1 (de) | Substituierte imidazolyl-propensaeurederivate | |
EP1047684B1 (de) | Substituierte alpha,beta-anellierte butyrolactone | |
DE60002733T2 (de) | Diester prodrugs von decahydroischinoline-3-carbonsäure | |
DE3630903A1 (de) | Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel | |
WO1999036418A1 (de) | Substituierte bicyclische lactone | |
DE3806549A1 (de) | 7-oxabicycloheptan-substituierte aminoprostaglandin-analoge | |
DE69427262T2 (de) | Bizyklische Verbindungen als EAA Rezeptor Antagonisten | |
DD279238A5 (de) | Verfahren zur herstellung von benzocycloheptenderivaten | |
DE69029861T2 (de) | N-acyl-substituierte azazyklische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
AT507039A1 (de) | Verfahren zum herstellen von hochreinen benzazepinderivaten | |
DE69019007T2 (de) | Cyclohexanacetamid-Derivate. | |
DE19932621A1 (de) | Neue substituerte alpha, beta-anellierte Butyrolactone | |
WO2000050421A1 (de) | Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
WO1999036417A1 (de) | SUBSTITUIERTE β,η-ANELLIERTE LACTONE | |
EP0113880A2 (de) | Neue 2-Azabicyclo(2.2.1)heptan-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie 2-Azabicyclo(2.2.1)heptan-Derivate als Zwischenprodukte und Verfahren zu deren Herstellung | |
CH556837A (de) | Verfahren zur herstellung neuer spiroindanpyrrolidinderivate. | |
EP0595166B1 (de) | 4-Heterocyclyl substituierte Dihydropyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000817 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE ES FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20010611 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020523 |